Patents by Inventor Wenbin Ying

Wenbin Ying has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160376229
    Abstract: This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Roger Adami, Hao Bai, John Gaudette, Bharat Majeti, Seiji Nukui, Kwok Yin Tsang, Hai Wang, Haiqing Ying, Wenbin Ying
  • Patent number: 9456984
    Abstract: What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: October 4, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Publication number: 20160215286
    Abstract: This invention provides compositions and methods for preventing or treating a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising RNAi molecules, which RNAi molecules can be active in reducing expression of Hsp47, or a combination of RNAi molecules active for Hsp47 and p21.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 28, 2016
    Inventors: Yoshiro Niitsu, Akihiro Yoneda, Yasuyuki Tamura, Kenjirou Minomi, Bharat Majeti, Jihua Liu, Yun Liu, Wenbin Ying
  • Publication number: 20160208254
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding GST-?; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 21, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Cima Cina, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
  • Publication number: 20160208265
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2?-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 21, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Cima Cina, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
  • Publication number: 20160208255
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding p21; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 21, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Jens Harborth, Cima Cina, Kwok Yin Tsang, Wenbin Ying, Hirokazu Takahashi
  • Publication number: 20160208256
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2?-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 21, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Jens Harborth, Cima Cina, Kwok Yin Tsang, Wenbin Ying, Hirokazu Takahashi
  • Publication number: 20160186183
    Abstract: This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-?.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Hiroki Nishita, Yusuke Nakashima, Miyono Miyazaki, Keiko Kajiwara, Jihua Liu, Li Wang, Jens Harborth, Bharat Majeti, Roger Adami, Wenbin Ying
  • Publication number: 20160186182
    Abstract: This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-?, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Yoshiro Niitsu, Kenjirou Minomi, Bharat Majeti, Jens Harborth, Li Wang, Jihua Liu, Yun Liu, Roger Adami, Wenbin Ying
  • Patent number: 9308267
    Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: April 12, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
  • Publication number: 20160074514
    Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    Type: Application
    Filed: October 1, 2015
    Publication date: March 17, 2016
    Inventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
  • Publication number: 20150283253
    Abstract: Polymer conjugates characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the polymer backbone are useful for preparing drug encapsulated polymer hydrotropes and compositions. Such materials are useful in methods for delivering the drug into cells, and for the treatment and alleviation of diseases and disorders such as cancer.
    Type: Application
    Filed: April 6, 2015
    Publication date: October 8, 2015
    Inventors: Wenbin YING, Kwok Yin Tsang, Hao Bai, Haiqing Yin, Jihua Liu, Li Wang
  • Publication number: 20140356413
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 4, 2014
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Patent number: 8741867
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: June 3, 2014
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Patent number: 8664376
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 4, 2014
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Publication number: 20130330401
    Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 12, 2013
    Applicant: Nitto Denko Corporation
    Inventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
  • Publication number: 20130071467
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.
    Type: Application
    Filed: June 8, 2012
    Publication date: March 21, 2013
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Publication number: 20130071478
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
    Type: Application
    Filed: June 8, 2012
    Publication date: March 21, 2013
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Patent number: 7732146
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: June 8, 2010
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K.C.
  • Patent number: 7514225
    Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: April 7, 2009
    Assignee: Avanir Pharmaceuticals
    Inventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.